Skip to main
DWTX

DWTX Stock Forecast & Price Target

DWTX Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Dogwood Therapeutics is a development-stage biopharmaceutical company with a positive outlook due to its strong pipeline of potential treatments for chronic neuropathic pain and neuropathy, a significant unmet medical need. The company's licensing of its anti-viral assets to PridCor Therapeutics provides potential for future milestone payments and royalties. However, the lack of near-term clinical milestones may limit immediate impact and the stock's potential growth.

Bears say

Dogwood Therapeutics is a development-stage biopharmaceutical company with a focus on treating chronic neuropathic pain and neuropathy. Despite its promising pipeline, the company has yet to generate any revenues and is still in the pre-revenue stage. With a projected net loss of $0.56 per share for 2026 and only $13.2 million in cash and cash equivalents, the stock may face challenges in the near future.

DWTX has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Dogwood Therapeutics, Inc. and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Dogwood Therapeutics, Inc. (DWTX) Forecast

Analysts have given DWTX a Strong Buy based on their latest research and market trends.

According to 1 analysts, DWTX has a Strong Buy consensus rating as of Aug 28, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $12, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $12, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Dogwood Therapeutics, Inc. (DWTX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.